

TUMOR NECROSIS FACTOR INHIBITORS: UTILITY OF PHARMACOKINETICS MONITORING IN INFLAMMATORY BOWEL DISEASE MANAGEMENT



Llinares Esquerdo M, Martínez Pérez S, Pomares Bernabeu M, Soriano-Irigaray L, Garcia Monsalve A, Navarro Ruiz A.
Hospital General Universitario de Elche, Pharmacy Department.

BACKGROUND:

Infliximab(IFX) and adalimumab(ADA) are two monoclonal antibodies (inhibitors of tumor necrosis factor alpha (anti-TNF)) that have revolutionized the management of patients with inflammatory bowel disease (IBD). However, it's required an adequate individualization of the therapy in order to optimize it.


PURPOSE:

To describe the pharmacokinetic determinations of serum levels of IFX and ADA in patients with inflammatory bowel disease and to evaluate its impact on clinical decision making.


MATERIAL AND METHODS:

Retrospective observational study (2017) in a General Hospital.

Variables collected to request monitoring: sex, age, weight, drug, diagnosis and reason for the request.



RESULTS:



DISCUSSION AND CONCLUSION:

Results show a high percentage of patients with inadequate anti-TNF serum levels that support the use of anti-TNF pharmacokinetic monitoring as an useful tool in clinical decision making.

ACKNOWLEDGEMENTS: To my workmates, thank you.